Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells 695 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 695 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $20,516.40. Following the completion of the sale, the general counsel now directly owns 144,299 shares in the company, valued at approximately $4,259,706.48. The trade was a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Apellis Pharmaceuticals Stock Up 3.3 %

Shares of Apellis Pharmaceuticals stock traded up $0.99 during trading hours on Thursday, hitting $30.46. 232,907 shares of the company’s stock traded hands, compared to its average volume of 1,954,741. The stock has a 50 day simple moving average of $32.20 and a 200-day simple moving average of $32.96. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company has a market cap of $3.79 billion, a PE ratio of -14.99 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the business posted ($1.17) EPS. The business’s revenue for the quarter was up 78.3% on a year-over-year basis. Equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter worth $27,000. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Capital Performance Advisors LLP bought a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $56,000. KBC Group NV lifted its position in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after acquiring an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on APLS shares. Scotiabank cut their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. William Blair started coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating on the stock. Citigroup cut their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday. Finally, Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).